This module uses fundamental data of Tonix Pharmaceuticals to approximate its Piotroski F score. Tonix Pharmaceuticals F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Tonix Pharmaceuticals Holding. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Tonix Pharmaceuticals financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Tonix Pharmaceuticals Altman Z Score, Tonix Pharmaceuticals Correlation, Tonix Pharmaceuticals Valuation, as well as analyze Tonix Pharmaceuticals Alpha and Beta and Tonix Pharmaceuticals Hype Analysis.
Tonix
Piotroski F Score
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Cash Per Share
Pocfratio
Payout Ratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Dividend Payout Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Days Of Inventory Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Cashflows From Financing Activities
Sale Purchase Of Stock
Net Borrowings
Stock Based Compensation
Total Cashflows From Investing Activities
Depreciation
Other Non Cash Items
Dividends Paid
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Exchange Rate Changes
Investments
Change To Operating Activities
Issuance Of Capital Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Debt
Retained Earnings
Cash
Cash And Short Term Investments
Net Receivables
Common Stock Total Equity
Common Stock Shares Outstanding
Short Term Investments
Liabilities And Stockholders Equity
Other Stockholder Equity
Total Liab
Total Current Assets
Common Stock
Accounts Payable
Short Long Term Debt Total
Other Liab
Net Tangible Assets
Property Plant And Equipment Net
Current Deferred Revenue
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Long Term Debt
Retained Earnings Total Equity
Non Current Liabilities Total
Capital Surpluse
Inventory
Other Current Assets
Deferred Long Term Liab
Property Plant And Equipment Gross
Accumulated Other Comprehensive Income
Short Term Debt
Property Plant Equipment
Net Invested Capital
Net Working Capital
Capital Stock
Capital Lease Obligations
Non Current Liabilities Other
Interest Expense
Selling General Administrative
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Tax Expense
Depreciation And Amortization
Total Revenue
Net Income From Continuing Ops
Research Development
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Non Operating Income Net Other
Interest Income
Net Interest Income
Reconciled Depreciation
Preferred Stock And Other Adjustments
Probability Of Bankruptcy
At this time, Tonix Pharmaceuticals' Short and Long Term Debt Total is relatively stable compared to the past year. As of 03/22/2025, Long Term Debt is likely to grow to about 4.9 M, while Net Debt To EBITDA is likely to drop 0.65. At this time, Tonix Pharmaceuticals' EV To Free Cash Flow is relatively stable compared to the past year. As of 03/22/2025, Current Ratio is likely to grow to 8.09, while Average Payables is likely to drop slightly above 266.3 K.
At this time, it appears that Tonix Pharmaceuticals' Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to Tonix Pharmaceuticals is to make sure Tonix is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Tonix Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Tonix Pharmaceuticals' financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Tonix Pharmaceuticals' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Tonix Pharmaceuticals in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
199.01
At this time, Tonix Pharmaceuticals' Book Value Per Share is relatively stable compared to the past year.
Tonix Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tonix Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tonix Pharmaceuticals' managers, analysts, and investors.
Environmental
Governance
Social
About Tonix Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tonix Pharmaceuticals Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tonix Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tonix Pharmaceuticals Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tonix Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tonix Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Tonix Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tonix Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tonix Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tonix Pharmaceuticals Holding to buy it.
The correlation of Tonix Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tonix Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tonix Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tonix Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
When running Tonix Pharmaceuticals' price analysis, check to measure Tonix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tonix Pharmaceuticals is operating at the current time. Most of Tonix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tonix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tonix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tonix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.